FDA advisers, frustrated by AZ's Imfinzi design, call for revamp of perioperative lung cancer trials

The FDA’s Oncologic Drugs Advisory Committee (ODAC) has unanimously called for a revamp of perioperative clinical trial designs in resectable non-small cell lung cancer (NSCLC) to include assessment of the contribution of each treatment phase.